2025-11-05

Q3 2025 Results

2025-08-05

Q2 2025 Results

2025-05-02

Q1 2025 Results

Financial data not available in provided content

2024-11-06

Q3 2024 Results

2024-08-05

Q2 2024 Results

Financial data not available in provided content

2024-05-03

Q1 2024 Results

2023-11-03

Q3 2023 Results

2023-08-07

Q2 2023 Results

2025-02-25

FY24 2024 Results

Data insufficient - no clear revenue or EPS figures available in provided content

📌 Data insufficient - filing content appears to be primarily XBRL taxonomy references without substantive financial data or business highlights

2024-02-26

FY 2023 Results

📌 Multiple strategic partnerships and acquisitions including Daiichi Sankyo antibody-drug conjugate collaboration (October 2023), Prometheus Biosciences acquisition (June 2023), and planned Harpoon Therapeutics acquisition (forecast completion by June 2024)

2025-10-30

Q3 Earnings

Third quarter 2025 earnings report

2025-09-09

Debt Offering

$6B notes offering with rates from floating to 5.7%

2025-07-29

Q2 Earnings + $3B Restructuring Program

$3B restructuring costs, $1.7B annual savings by 2027

2025-05-29

Annual Shareholder Meeting

13 directors elected, executive comp approved, 4 shareholder proposals rejected

2025-04-24

Q1 2025 Earnings

First quarter 2025 earnings results

2025-02-04

Q4 2024 Earnings

Fourth quarter and year end 2024 results reported

2024-11-22

New Director Elected, Bylaws Amended

Lal Karsanbhai elected to Board effective Jan 1, 2025; indemnification provisions updated

2024-10-31

Q3 Earnings

Q3 2024 earnings reported

2024-07-30

Q2 2024 Earnings

Second quarter 2024 earnings results

2024-05-30

€3.4B Debt Offering & Annual Meeting

€3.4B notes issued (3.25%-3.75% rates, 2032-2054 maturities); all directors re-elected

2024-04-25

Q1 2024 Earnings

Q1 2024 financial results reported

2024-02-20

Director Retirement

Peter C. Wendell retiring from Board at 2024 Annual Meeting (May 28, 2024)

2024-02-01

Q4 Earnings + $4B Restructuring Program

$4B restructuring costs through 2031, 60% non-cash

2023-11-28

Global Controller Change

Rita Karachun resigned, Dalton Smart III appointed effective Dec 4, 2023

2023-10-26

Q3 2023 Earnings

Third quarter 2023 earnings results reported

2023-08-01

Q2 2023 Earnings

Second quarter 2023 earnings reported

2023-05-26

Annual Shareholder Meeting

13 directors elected, executive compensation approved 91.30%

2023-05-17

Debt Offering

$5B multi-tranche notes offering, rates 4.05%-5.15%